Patents by Inventor Bryan Wayne KING
Bryan Wayne KING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240228503Abstract: The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.Type: ApplicationFiled: February 26, 2024Publication date: July 11, 2024Inventors: Adam K. CHARNLEY, Janos BOTYANSZKI, Xiaoyang DONG, Philip Gareth HUMPHREYS, Bryan Wayne KING, Kimberly Katherine MARCUS, Joseph PERO, Alexander Joseph REIF, Daohua ZHANG, Attiq RAHMAN(Deceased), Kenneth Allen NEWLANDER, Kenneth WIGGALL, Joshi RAMANJULU
-
Publication number: 20240180933Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.Type: ApplicationFiled: July 26, 2023Publication date: June 6, 2024Inventors: Andrew B. BENOWITZ, David T. FOSBENNER, Bryan Wayne KING, Stuart Paul ROMERIL
-
Patent number: 11771711Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.Type: GrantFiled: October 14, 2022Date of Patent: October 3, 2023Assignee: GlaxoSmith Kline Intellectual Property Development LimitedInventors: Andrew B. Benowitz, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
-
Publication number: 20230101987Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.Type: ApplicationFiled: October 14, 2022Publication date: March 30, 2023Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
-
Patent number: 10975056Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: GrantFiled: June 13, 2017Date of Patent: April 13, 2021Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
-
Patent number: 10940154Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.Type: GrantFiled: May 10, 2019Date of Patent: March 9, 2021Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
-
Patent number: 10933070Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.Type: GrantFiled: March 12, 2019Date of Patent: March 2, 2021Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
-
Publication number: 20190262356Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.Type: ApplicationFiled: May 10, 2019Publication date: August 29, 2019Inventors: Jae U. JEONG, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, JR., Daohua Zhang
-
Publication number: 20190201413Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.Type: ApplicationFiled: March 12, 2019Publication date: July 4, 2019Inventors: Jae U. JEONG, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, JR., Daohua Zhang
-
Publication number: 20190194166Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: June 13, 2017Publication date: June 27, 2019Inventors: Nicholas David ADAMS, Andrew B. BENOWITZ, María Lourdes Rueda BENEDE, Karen Anderson EVANS, David T. FOSBENNER, Bryan Wayne KING, Mei LI, Juan Ignacio LUENGO, William Henry MILLER, Alexander Joseph REIF, Stuart Paul ROMERIL, Stanley J. SCHMIDT, Roger J. BUTLIN, Kristen M. GOLDBERG, Allan M. JORDAN, Christopher S. KERSHAW, Ali RAOOF, Bohdan WASZKOWYCS
-
Patent number: 10292987Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.Type: GrantFiled: March 15, 2017Date of Patent: May 21, 2019Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
-
Patent number: 9556152Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.Type: GrantFiled: February 14, 2014Date of Patent: January 31, 2017Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Philip Anthony Harris, Bryan Wayne King
-
Publication number: 20170008878Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.Type: ApplicationFiled: September 21, 2016Publication date: January 12, 2017Inventors: Deepak BANDYOPADHYAY, Patrick M. EIDAM, Peter J. GOUGH, Philip Anthony HARRIS, Jae U. JEONG, Jianxing KANG, Bryan Wayne KING, Ami LAKDAWALA SHAH, Lara Kathryn LEISTER, Robert W. MARQUIS, JR., Attiq RAHMAN, Joshi M. RAMANJULU, Clark A. SEHON, Robert SINGHAUS, JR., Daohua ZHANG
-
Publication number: 20150353533Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.Type: ApplicationFiled: February 14, 2014Publication date: December 10, 2015Inventors: Deepak BANDYOPADHYAY, Patrick M. EIDAM, Peter J. GOUGH, Philip Anthony HARRIS, Jae U. JEONG, Jianxing KANG, Bryan Wayne KING, Ami LAKDAWALA SHAH, Lara Kathryn LEISTER, Robert W. MARQUIS, JR., Attiq RAHMAN, Joshi M. RAMANJULU, Clark A. SEHON, Robert SINGHAUS, JR., Daohua ZHANG